Treatment of hepatitis delta virus infection with interferon lambda
Pegylated interferon lambda-1a administered in varying dose regimens effectively reduces HDV viral load and improves liver function, addressing the limitations of existing treatments by achieving high response rates and sustained viral suppression.
Patent Information
- Application Number
- JP2024119242
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-04-09
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for hepatitis delta virus (HDV) infection, such as pegylated interferon alpha, suffer from high recurrence rates and lack long-term efficacy, necessitating the development of more effective therapies.
Administering pegylated interferon lambda-1a subcutaneously for at least 48 weeks, with varying dose regimens including 180 micrograms weekly, followed by adjustments to 120 or 80 micrograms weekly, to reduce HDV viral load and improve liver function markers.
The treatment achieves a significant reduction in HDV viral load, with up to 60% of subjects achieving undetectable levels and sustained viral response, along with improved liver function parameters, demonstrating superior efficacy compared to pegylated interferon alpha.
Smart Images

Figure 2024164015000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention provides methods for treating viral hepatitis caused by Hepatitis Delta Virus (HDV) infection and thus relates to the fields of chemistry, medicinal chemistry, medicine, molecular biology and pharmacology.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to Provisional Application Nos. 62 / 831,548 (filed April 9, 2019), 62 / 823,530 (filed March 25, 2019), and 62 / 721,763 (filed August 23, 2018), each of which is incorporated herein by reference.
[0003] Description of sequence listing submitted as a text file via EFS-WEB An official copy of the Sequence Listing has been provided electronically via EFS-Web as an ASCII Sequence Listing, filed under filename 097854-1152075-002410PC_SL.TXT, created on August 8, 2019, having a size of 1.97 MB, and filed contemporaneously herewith. The Sequence Listing contained in this ASCII document is a part of the present specification and is incorporated herein by reference in its entirety. [Background technology]
[0004] 2. Background of the Invention Hepatitis delta virus (HDV) causes the most severe form of chronic viral hepatitis. HDV exists as a coinfection with hepatitis B virus (HBV). Chronic HDV and HBV coinfection exacerbates pre-existing HBV-associated liver damage, leading to cirrhosis, hepatic decompensation and hepatocellular carcinoma. See Negro, Cold Spring Harb Perspect Med, 2014, 4:a021550; Hoener zu Siederdissen, Visc Med, 2016, 32:86-94; Lau, Hepatology, 1999, 30:546-549. Subjects coinfected with both HDV and HBV are more likely to die from complications of liver disease compared to subjects infected with HBV alone. See Alavian et al., J Res Med Sci, 2012, 17:967-974.
[0005] Interferon alpha therapy for the treatment of HDV has been reported. In the Hep-Net International Delta Intervention Trial 1 (HIDIT-1) trial published in 2011, 28% of subjects treated with pegylated interferon alpha-2a were found to have cleared HDV RNA 24 weeks after the end of treatment. Wedemeyer et al., N Engl J Med, 2011, 364:322-331. However, a 5-year long-term follow-up of subjects treated in the HIDIT-1 trial found that more than 50% of subjects showed late HDV RNA recurrence. Heidrich et al., Hepatology, 2014, 60:87-97.
[0006] In contrast to interferon alpha, which conveys its efficacy by signaling through interferon alpha receptors that are widely expressed by many different cell types, interferon lambda signals through a different type of receptor, the interferon lambda receptor, which has a limited cellular expression pattern. Interferon lambda also exhibits different antiviral activity than interferon alpha, due in part to differences in the expression of interferon receptors. In a comparative study of pegylated interferon alpha and pegylated interferon lambda for the treatment of HBV (Chan et al., J. Hepatology, 2016, 64:1011-1019), it was found that pegylated interferon lambda produces a more significant decline in viremia compared to pegylated interferon alpha at the midpoint of treatment (24 weeks), but by the end of the treatment period, there is no difference between pegylated interferon alpha and pegylated interferon lambda treatment, and after treatment, there is a greater virological rebound in the pegylated interferon lambda treatment group. HBV / HDV coinfected mice treated with pegylated interferon alpha for 4 weeks showed a 2.2 log reduction in HDV-RNA levels, whereas mice treated with pegylated interferon lambda for 4 weeks showed a 1.5 log reduction in HDV-RNA levels ( Giersch et al., 2013 ). Summary of the Invention [Problem to be solved by the invention]
[0007] To date, the efficacy of long-term pegylated interferon lambda therapy for the treatment of HDV has not been reported. There remains a need for agents to treat HDV infection. [Means for solving the problem]
[0008] Summary of the Invention In one aspect, a method for treating hepatitis delta virus (HDV) infection in a human subject is provided. In one embodiment, the method comprises subcutaneously administering a therapeutically effective amount of pegylated interferon lambda-1a to the subject for at least 48 weeks.
[0009] In some embodiments, pegylated interferon lambda-1a is administered at a dose of 180 micrograms once a week (QW). In some embodiments, pegylated interferon lambda-1a is administered at a dose of 120 micrograms QW. In some embodiments, (i) pegylated interferon lambda-1a is administered at 160-180 micrograms / week in a first treatment period, followed by 150-70 micrograms / week in a second treatment period; or (ii) 180 micrograms / week in a first treatment period, followed by 170-120 micrograms / week in a second treatment period, where the doses of (i) and (ii) may be divided into more than one administration per week.
[0010] In one embodiment, the method comprises administering pegylated interferon lambda-1a at a dose of 180 micrograms QW in a first treatment period, followed by a dose of 120 micrograms QW in a second treatment period. In one embodiment, the method comprises administering pegylated interferon lambda-1a at a dose of 120 micrograms QW in a first treatment period, followed by a dose of 80 micrograms QW in a second treatment period. In one embodiment, the first treatment period is longer than the second treatment period. In one embodiment, the second treatment period is longer than the first treatment period. In one embodiment, the first treatment period and the second treatment period are the same length. In one embodiment, the first treatment period is at least 8 weeks. In one embodiment, the first treatment period is 8-12 weeks. In one embodiment, the method further comprises administering pegylated interferon lambda-1a at an 80 microgram dose QW in a third treatment period. In one embodiment, the method comprises administering a 180 microgram dose of pegylated interferon lambda-1a QW in a first treatment period, followed by a 120 microgram dose QW in a second treatment period, followed by 60 microgram to 110 microgram doses QW in a third treatment period.
[0011] In some embodiments, the method comprises administering pegylated interferon lambda-1a in a first dose of 180 micrograms QW in a first treatment period, a second dose of 120 micrograms QW in a second treatment period, and a third dose of 110-80 micrograms QE in a third treatment period. In some embodiments, the first treatment period has a duration of at least 8 weeks. In some embodiments, the first treatment period is 8-12 weeks, 1-8 weeks, or 2-12 weeks.
[0012] In some embodiments, the treatment results in a reduction in HDV viral load in the subject of at least 2.0 log HDV RNAIU / mL serum. In some embodiments, the treatment results in a HDV viral load below the limit of detection (BLQ). In some embodiments, before treatment begins, the subject has a serum alanine aminotransferase (ALT) level above the upper limit of normal (ULN), and the course of treatment improves the subject's serum ALT level to a level below ULN.
[0013] In one embodiment, prior to treatment, the subject receives up to about 10 4 Have a baseline viral load of HDV RNA copies / mL serum or plasma.
[0014] In one embodiment, subjects with low viral load have a higher BLQ response percentage after 48 and 24 weeks of treatment.
[0015] In one embodiment, in the Lambda 180 μg treatment group, response rates differed between subjects with high (>4 log) versus low (≦4 log) baseline viral load. In one embodiment, at week 48, 38-43% and 33-40% of subjects with high versus low baseline viral load, respectively, reached HDV RNA levels at the BLQ. In another embodiment, at week 72, the difference between the two groups was more pronounced, with 50-60% of subjects with low baseline viral load reaching the BLQ versus 25-29% of those with high baseline viral load meeting this endpoint.
[0016] In one embodiment, 25-29% and 33-40% of subjects with high versus low baseline viral load, respectively, achieved undetectable HDV RNA levels (BLQ) at week 48. In one embodiment, at week 72, the difference between these two groups was consistent with the week 48 measurement, with 33-40% of subjects with low baseline viral load reaching BLQ versus 25-29% of those with high baseline viral load meeting this endpoint.
[0017] In some embodiments, the method further comprises administering to the subject a nucleoside or nucleotide analog, hi some embodiments, the nucleoside or nucleotide analog is lamivudine, adefovir, telbivudine, entecavir, or tenofovir.
[0018] In certain embodiments, the subject has compensated liver disease with or without cirrhosis. In certain embodiments, the subject has compensated liver disease with cirrhosis.
[0019] Other aspects and embodiments are described below. [Brief description of the drawings]
[0020] [Figure 1] Interferon lambda shows rapid reduction in HDV RNA by week 24. Mean change in log HDV RNA by week 24 is shown.
[0021] [Diagram 2] Interferon lambda shows rapid reduction in HDV RNA through week 48. Mean log change in HDV RNA through week 48 is shown. Inset table shows number and percentage of subjects showing ≧2 log10 reduction in HDV RNA at weeks 4, 8, 12, 24 and 48, as well as number and percentage of subjects showing HDV RNA levels below the limit of quantification.
[0022] [Diagram 3] Interferon lambda at 180mcg results in a higher response rate compared to interferon lambda at 120mcg. The graph shows the mean HDV RNA reduction by week 48 for subjects treated with 180mcg or 120mcg interferon lambda. The inset table shows the mean log reduction in HDV RNA at 120mcg and 180mcg doses, the number and percentage of subjects with a ≧2 log reduction in HDV RNA, and the number and percentage of subjects with HDV RNA levels below the limit of quantification.
[0023] [Figure 4] Demonstrates durability of viral response.
[0024] [Diagram 5] Shows ALT normalization with interferon lambda.
[0025] [Figure 6] Together with Table 5, this shows that the response to interferon lambda is durable.
[0026] [Figure 7] HBsAg reduction with interferon lambda.
[0027] [Figure 8] 1 shows the time course of HDV RNA in responders at 48 weeks of treatment.
[0028] [Figure 9] This further demonstrates the durability of the viral response.
[0029] [Figure 10] A composite endpoint of ALT normalization and > 2 log10 reduction or BLQ is shown.
[0030] [Figure 11] Comparison of Lambda vs. PEG INF alpha showing 0% sustained viral response (SVR) achieved with PEG INF alpha and 36% sustained viral response (DVR) achieved with Lambda. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] Detailed Description of the Invention I. Definition The scope of the present invention is limited only by the appended claims, and the terms used herein are intended to describe only specific embodiments and are not intended to be limiting. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. In this specification and the claims that follow, reference is made to a number of terms that shall be defined to have the following meanings unless a different intention is apparent. In some cases, terms that have commonly understood meanings are defined herein for clarity and / or ready reference, and the inclusion of such definitions herein should not be construed as representing a substantial difference to the definition of the term as commonly understood in the art.
[0032] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are described herein. All technical and patent literature cited herein is incorporated by reference in its entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
[0033] All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (-) by increments of 0.1 or 1.0, as appropriate. It should be understood that all numerical designations are preceded by the term "about," even if not always explicitly stated.
[0034] Singular terms include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a compound" includes a plurality of compounds.
[0035] The term "administration" refers to introducing the disclosed compound, composition or agent into a host, such as human.Herein, one preferred administration route for administering agent is subcutaneous administration.Other administration routes are intravenous administration and oral administration.
[0036] The term "baseline" refers to measurements (eg, viral load, subject status, ALT levels) obtained prior to a course of treatment, unless otherwise specified or apparent from the context.
[0037] The term "comprising" is intended to mean that the compounds, compositions, and methods include the recited elements, but do not exclude other elements. "Consisting essentially of," when used to define compounds, compositions, and methods, is intended to mean excluding other elements that materially affect the basic and novel characteristics of the claimed invention. Embodiments defined by each of these transitional phrases are within the scope of the invention.
[0038] The terms "treatment course" and "treatment course" are used interchangeably herein and refer to medical intervention after a subject is diagnosed, for example, infected with HDV and requires medical intervention. Medical intervention includes, but is not limited to, administration of medication for a period of time, typically at least one month, typically several months or months or years for a HDV-infected subject.
[0039] The term "HDV RNA viral load" or "viral load" of a human serum or plasma sample refers to the amount of HDV RNA in a given volume of a human serum or plasma sample. HDV RNA is generally detected by a quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) assay. In such an assay, the amount of signal generated during the assay is proportional to the amount of HDV RNA in the sample. The signal from the test sample is compared to the signal of a dilution series of a quantified hepatitis delta RNA standard, and the copy number of genome copies is calculated. See, for example, Kodani et al., 2013, J. Virol. Methods, 193(2), 531; Karatayli et al., 2014, J. Clin. Virol, 60(1), 11. HDV RNA viral load can be reported using RNA copies per mL serum (or plasma) or International Units (IU) per mL serum (or plasma). See Chudy et al., 2013, Collaborative Study to establish a World Health Organization International standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays.” WHO Expert Committee on Biological Standardization WHO / BS / 2013.2227. Commercially available assays are available from ARUP Laboratories (Salt Lake City, UT). The limit of detection for the ARUP HDV RNA assay is reported to be 31 IU / mL. Analytik Jena AG (Germany) offers the RoboGene® HDV RNA Quantitation Kit 2.0, which is CE-IVD certified to WHO standards, to assess response to antiviral treatment. The limit of detection for the RoboGene® assay is reported to be 6 IU / mL."Viral load" without a specific unit (e.g., "viral load less than 100") refers to copies of HDV RNA per mL of serum unless otherwise indicated or clear from the context. Unless otherwise specified, reference to "below the level of detection" means less than 15 IU / mL.
[0040] HDV level is log 10 The HDV RNA level is presented using units. HDV RNA levels can be presented in units of "RNA copies per mL" or "International Units (IU) per mL". See, Chudy et al., 2013, Collaborative Study to establish a World Health Organization International standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays." WHO Expert Committee on Biological Standardization WHO / BS / 2013.2227. Both units are used herein. If used herein, a statement of "HDV RNA copies per mL" (e.g., as shown in the Examples, when not otherwise specified and does not include a statement related to clinical trial results) should be read as "HDV RNA copies / mL or HDVIU / mL" for the purposes of or as a basis for the description of the specification. When a specific amount of HDV RNA copies per mL is described, a multiplier of 1.2 can be applied to convert the amount of HDV RNA copies / mL to an amount of IU / mL for the description and support of the specification. For example, "120 HDV RNA copies per mL" should be read as "120 copies / mL or 100 IU / mL."
[0041] Changes in HDV RNA levels can be expressed as a "log reduction" following the usual convention in virology. For example, a 1 log reduction in viral load (i.e., -1 log 10 ) (e.g., 7log 10From 6 logs 10 ) is a 10-fold reduction, a 2 log reduction in viral load (i.e., -2 log 10 ) For example, 7log 10 From 5 logs 10 A reduction from 4 log RNA copies / mL to 3 log RNA copies / mL is a 100-fold reduction. 10 IU / mL to 3 logs 10 This is equivalent to a reduction to IU / mL.
[0042] The term "HDV infection" with respect to a human (host) refers to the fact that the host is suffering from HDV infection. Typically, HDV-infected human hosts have at least about 2 log HDV infection per mL of host serum or plasma. 10 HDV RNA copies or 10 HDV-RNA per mL of host serum or plasma 2 copies, often at least about 3 log per mL of host serum or plasma 10 HDV RNA copies or 10 HDV-RNA per mL of host serum or plasma 3 copies, and in many cases, at least about 4 log / mL of host serum or plasma, particularly for subjects not receiving any treatment. 10 HDV RNA copies or 10 HDV-RNA per mL of host serum or plasma 4 copies, e.g., about 4 log per mL of host serum or plasma 10 HDV RNA copies: 8 logs per mL of host serum or plasma 10 HDV RNA copies or 10 HDV-RNA per mL of host serum or plasma 4 ~10 8The human host has an HDV RNA viral load, such as 100 copies.As used herein, the term "chronic HDV infection" refers to a HDV infection that has persisted in the human host for at least 6 months, as described by a positive HDV antibody (Ab) test and / or detectable by qRT-PCR.The diagnosis and pathogenesis of HDV are described, for example, in Wedemeyer et al., Nat. Rev. Gastroenterol. Hepatol, 2010, 7:31-40.
[0043] The term "lower limit of quantification" refers to the lowest concentration of a substance of an analyte (e.g., viral titer) that can be reliably quantified by a particular assay within given confidence limits.
[0044] The terms "subject," "host," or "subject" are used interchangeably and refer to a human infected with HDV, including a subject that was previously infected with HDV and has been cleared of the virus.
[0045] The term "pharmaceutical composition" is meant to encompass compositions suitable for administration to a subject. Generally, a "pharmaceutical composition" is preferably sterile and free of contaminants that may induce an undesired reaction in a subject (e.g., one or more compounds in the pharmaceutical composition are of pharmaceutical grade). Pharmaceutical compositions can be designed for administration to a subject or subjects in need thereof by a number of different routes of administration, including oral, intravenous, buccal, rectal, parenteral, intraperitoneal, intradermal, intratracheal, intramuscular, subcutaneous, inhalation, and the like.
[0046] A "sustained reduction" in HDV viral load is defined as a reduction in viral load (e.g., at least 1.5 log) over a period of time (e.g., 1 month, 3 months, 6 months, 1 year, or longer). 10 HDV RNAIU / mL serum, at least 2.0 log 10 HDV RNA copies / mL serum or at least 2.5 logs 10 Sustained reduction means a reduction in HDV RNA IU / mL serum or a reduction in HDV RNA to undetectable levels. Sustained reduction can be during the period while the treatment course is still ongoing or after the treatment course has ended.
[0047] The term "therapeutically effective amount" as used herein refers to an amount of an embodiment of an administered substance (e.g., a compound, inhibitor or drug) that treats to some extent a disease, disorder or condition, e.g., relieves one or more of the symptoms of the disease or infection being treated and / or prevents to some extent one or more of the symptoms of the disease or infection that the subject being treated has or is at risk of developing.
[0048] The terms "treatment" and "treating" are defined as addressing a disease, disorder, or condition with an agent to reduce or ameliorate the pharmacological and / or physiological effects and / or symptoms of the disease, disorder, or condition. As used herein, "treatment" includes any treatment of a disease in a human subject, including (a) reducing the risk of disease development in a subject determined to be susceptible to the disease but not yet diagnosed as infected with the disease, (b) inhibiting the manifestation of the disease, and / or (c) relieving the disease, i.e., causing regression of the disease and / or relieving one or more disease symptoms. "Treatment" is also meant to encompass the delivery of an inhibitor that provides a pharmacological effect even in the absence of a disease or condition. For example, "treatment" includes the delivery of an agent that provides an enhanced or desirable effect in a subject (e.g., reducing viral load, reducing disease symptoms, etc.).
[0049] The term "undetectable" or "below the level of detection" or "BLD" as used in reference to HDV RNA levels means that no HDV RNA copies are detected by the assay method used. In one embodiment, the assay is quantitative RT-PCR.
[0050] As used herein, the term "sustained virologic response" or "DVR" refers to a post-treatment response in a subject with HDV RNA below the limit of quantification (BLQ) 1 week or more after the end of treatment or 2-12 weeks after last treatment or 12-24 weeks after last treatment or 12-48 weeks after last treatment.
[0051] II. Treatment Method In one embodiment, the present invention provides a method for treating HDV infection by administering interferon lambda therapy to a HDV-infected subject. In one embodiment, a pegylated form of interferon lambda (e.g., pegylated interferon lambda-1a) is administered. In one embodiment, the subject receiving interferon lambda therapy (e.g., pegylated interferon lambda therapy) is also treated with an antiviral nucleoside or nucleotide analog (e.g., anti-HBV nucleotide or nucleoside analog). In one embodiment, the subject receiving interferon lambda therapy (e.g., pegylated interferon lambda therapy) is also treated with lonafarnib therapy or lonafarnib and ritonavir therapy, for example, during the period of interferon lambda therapy or part of the period during which interferon lambda therapy is administered. In one embodiment, the subject receiving interferon lambda therapy (e.g., pegylated interferon lambda therapy) is not administered with an antiviral nucleoside or nucleotide analog therapy. In certain embodiments, the subject receiving interferon lambda therapy (eg, pegylated interferon lambda therapy) is not administered lonafarnib therapy or lonafarnib and ritonavir therapy.
[0052] Interferon lambda Interferons are polypeptides that inhibit viral replication and cell proliferation and regulate immune responses. Based on the type of receptor that mediates their signal transduction, human interferons have been classified into three major types (type I, type II, and type III). All type I IFNs bind to a specific cell surface receptor complex known as the IFN-alpha receptor (IFNAR), which consists of the IFNAR1 and IFNAR2 chains. The type I interferons present in humans are IFN-alpha, IFN-beta, IFN-epsilon, and IFN-omega. Type II IFNs bind to the IFN-gamma receptor (IFNGR), which consists of the IFNGR1 and IFNGR2 chains. The type II interferon in humans is IFN-gamma. The type III interferon group consists of three IFN-lambda molecules, called IFN-lambda 1, IFN-lambda 2, and IFN-lambda 3 (also called IL29, IL28A, and IL28B, respectively). These IFNs signal through a receptor complex consisting of IL10R2 (also called CRF2-4) and IFNLR1 (also called CRF2-12).
[0053] The term "interferon-lambda" or "IFN-lambda" as used herein includes natural IFN-lambda; synthetic IFN-lambda; derivatized IFN-lambda (e.g., PEGylated IFN-lambda, glycosylated IFN-lambda, etc.); and analogs of natural or synthetic IFN-lambda. In certain embodiments, IFN-lambda encompasses derivatives of IFN-lambda that have been derivatized (e.g., chemically modified compared to the native peptide) to alter certain properties, such as serum half-life. Thus, the term "IFN-lambda" includes IFN-lambda that have been derivatized with polyethylene glycol ("PEGylated IFN-lambda"), and the like. Pegylated IFN-lambda (e.g., PEGylated IFN-lambda-1a) and methods for making same are described, for example, in U.S. Patents 6,927,040, 7,038,032, 7,135,170, 7,157,559 and 8,980,245; and WO2005 / 097165, 2007 / 012033, 2007 / 013944 and 2007 / 041713; all of which are incorporated herein by reference in their entirety. In one embodiment, the IFN-lambda is an IFN-lambda described in PCT / US2017 / 018466, which is incorporated herein by reference in its entirety. In one embodiment, the PEGylated IFN-lambda-1a has a structure described in U.S. Patent 7,157,559, which is incorporated herein by reference in its entirety.
[0054] In certain embodiments, the interferon for use in the therapeutic methods described herein is pegylated IFN-lambda 1 (e.g., pegylated IFN-lambda-1a), pegylated IFN-lambda-2, or pegylated IFN-lambda-3. In certain embodiments, the interferon is pegylated IFN-lambda 1 (e.g., pegylated IFN-lambda-1a).
[0055] In one embodiment, the pegylated IFN-λ1 has the following amino acid sequence (the lines indicate the intrachain disulfide bonds) [SEQ ID NO:1]: [ka]
[0056] Target population In some embodiments, the subject treated with interferon lambda described herein is a subject with HDV infection, acute HDV infection or chronic HDV infection. In some embodiments, the subject treated has a persistent chronic HDV infection for at least 6 months, documented by a positive HDV antibody (Ab) test and / or HDV RNA detectable by qRT-PCR. In some embodiments, the subject treated with the therapeutic methods described herein is a subject with an acute HDV infection that is newly diagnosed or otherwise believed to have been absent in the subject for 6 months or more. HDV diagnosis and pathological testing are described, for example, in Wedemeyer et al., Nat. Rev. Gastroenterol. Hepatol, 2010, 7:31-40. HDV is known to exist in various subtypes. The methods described herein are suitable for treating all HDV subjects, regardless of HDV subtype. In some embodiments, the subject is an adult (18 years or older), and in other embodiments, the subject is a child.
[0057] In one embodiment, the subject being treated has at least 10 2 HDV RNA copies or at least 10 per mL of serum or plasma 2 IU, e.g., at least 10 per mL of serum or plasma 3 HDV RNA copies or at least 10 3 IU, at least 10 per mL of serum or plasma 4 HDV RNA copies or at least 10 4 IU, at least 10 per mL of serum or plasma 5 HDV RNA copies or at least 10 5 IU, at least 10 per mL of serum or plasma 6 HDV RNA copies or at least 10 6 IU, at least 10 per mL of serum or plasma 7 HDV RNA copies or at least 10 7 IU, at least 10 per mL of serum or plasma 8HDV RNA copies or at least 10 8 In one embodiment, the subject to be treated has a baseline viral load of up to about 10 4 HDV RNA copies / mL serum or plasma or up to approximately 10 4 In one embodiment, the subject to be treated has a baseline viral load of up to about 10 5 HDV RNA copies / mL serum or plasma or up to approximately 10 5 In one embodiment, the subject to be treated has a baseline viral load of up to about 10 6 HDV RNA copies / mL serum or plasma or up to approximately 10 6 Have a baseline viral load of IU / mL serum or plasma.
[0058] In some embodiments, HDV viral load is measured using serum samples from subjects. In some embodiments, HDV viral load is measured using plasma samples from subjects. In some embodiments, viral load is measured by quantitative RT-PCR. qRT-PCR assays for quantifying HDV RNA in serum or plasma are known in the art, for example, as described above.
[0059] In some embodiments, the subject to be treated exhibits one or more symptoms of liver dysfunction. In some embodiments, the subject exhibits one or more liver function parameters that are outside the normal parameters of healthy controls (e.g., subjects not infected with HDV or HBV). In some embodiments, the liver function parameters are selected from the group consisting of serum albumin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and prothrombin activity. In some embodiments, the subject has a serum ALT level that is at least twice (e.g., at least twice, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least ten times, or more) the upper limit of normal (ULN). Liver function parameters are described in the literature. See, for example, Limdi et al., Postgrad Med J, 2003, 79:307-312. Methods for measuring these liver function parameters are known in the art and are commercially available.
[0060] In some embodiments, the subject has compensated liver disease (e.g., classified according to the Child-Turcotte-Pugh classification system) with or without cirrhosis. The Child-Turcotte-Pugh classification system is used to classify the severity of liver disease and is recognized by those skilled in the art to be determined by evaluating serum albumin levels, bilirubin levels, international normalized ratio of prothrombin time levels, ascites formation, and encephalopathy. In some embodiments, the subject has a Child-Turcotte-Pugh score of 5-6 (Class A). In some embodiments, the subject has a Child-Turcotte-Pugh score of 1-6. In some embodiments, the subject has a Child-Turcotte-Pugh score of 1-2 or 1-3 or 2-4 or 3-4 or 2-5 or 3-5 or 2-6. In some embodiments, the subject has compensated liver disease with cirrhosis. In some embodiments, the subject has compensated liver disease without cirrhosis.
[0061] In some embodiments, the subject is diagnosed with chronic hepatitis, e.g., as determined by one or more of liver biopsy, liver function tests, ultrasound, hepatic venous pressure gradient (HVPG) measurement, ALT levels, other blood tests, or albumin levels. In some embodiments, the biopsy is within 6 months prior to treatment. In some embodiments, the biopsy is within 18 months prior to initiation of treatment with the methods provided herein. In some embodiments, the biopsy is within 1 day to 24 months prior to treatment. In some embodiments, the subject has evidence of chronic hepatitis based on a liver biopsy within 6 months prior to screening. In some embodiments, the subject has a serum alanine aminotransferase (ALT) level above the upper limit of normal (ULN) within 24 weeks prior to treatment and / or at the start of treatment, within 24 months prior to treatment, 24 months to 1 month prior to treatment, or 12 months to 1 day prior to treatment. In various embodiments, the subject meets one or more of the independently selected eligibility criteria in Example 1.
[0062] Interferon lambda dosing regimen In some embodiments, the interferon lambda treatment comprises administering to the subject interferon lambda (e.g., pegylated interferon lambda-1a) at a dose of 180 micrograms (mcg) / week, 120 mcg / week, 110 mcg / week, 100 mcg / week, 90 mcg / week, 80 mcg / week, 120-70 mcg / week, 200-120 mcg / week, 170-130 mcg / week. In some embodiments, the interferon lambda is administered at a dose of 180 mcg QW. In some embodiments, the interferon lambda is administered at a dose of 90 mcg twice weekly. In some embodiments, the interferon lambda is administered at a dose of 90 mcg every 3-4 days. In some embodiments, the interferon lambda is administered at a dose of 80 mcg twice weekly. In one embodiment, interferon lambda is administered at a dose of 80 mcg every 3-4 days. In one embodiment, interferon lambda is administered at a dose of 100-70 mcg twice weekly. In one embodiment, interferon lambda is administered at a dose of 100-70 mcg every 3-4 days. In one embodiment, interferon lambda is administered at a dose of 120 mcg QW. In one embodiment, interferon lambda is administered at a dose of 80 mcg QW.
[0063] In some embodiments, a subject being treated for HDV infection has an adjustment in the dosing regimen of interferon lambda therapy during the course of treatment. In some embodiments, the subject receives a dose reduction of interferon lambda, where one or more subsequent doses are lower than one or more previous doses. In some embodiments, if the subject exhibits unacceptable side effects, the dose is reduced. In some embodiments, during the course of treatment with interferon lambda, the subject may receive multiple dose reductions. In some embodiments, the dose administered to the subject is not reduced prior to 8 weeks of treatment with the first dose (e.g., a first dose of 180 mcg QW) or prior to 1 week or 2 weeks or 3 weeks or 4 weeks or 5 weeks or 6 weeks or 7 weeks of treatment with the first dose. In some embodiments, the dose administered to the subject is not reduced prior to 9-12 weeks of treatment with the first dose (e.g., a first dose of 180 mcg QW).
[0064] In some embodiments, the interferon lambda treatment comprises administering interferon lambda to the subject at a dose of 180 micrograms / week for a first treatment period, followed by administering interferon lambda to the subject at a dose of 120 micrograms / week for a second treatment period. In some embodiments, the length of the first treatment period is the same as the length of the second treatment period. In some embodiments, the first treatment period and the second treatment period are of different duration. In some embodiments, the first treatment period (i.e., interferon lambda at a dose of 180 mcg / week) is longer than the second treatment period (i.e., interferon lambda at a dose of 120 mcg / week). In some embodiments, the second treatment period (i.e., interferon lambda at a dose of 120 mcg / week) is longer than the first treatment period (i.e., interferon lambda at a dose of 180 mcg / week). In some embodiments, the interferon lambda treatment further comprises administering interferon lambda at a dose of 110-80 micrograms / week to the subject for a third treatment period. In some embodiments, the length of the third treatment period is the same as the length of the first and / or second treatment period. In some embodiments, the third treatment period and the first and / or second treatment period are of different duration. In some embodiments, the third treatment period (i.e., interferon lambda at a dose of 110-80 mcg / week) is longer than the first and / or second treatment period. In some embodiments, the third treatment period (i.e., interferon lambda at a dose of 80 mcg / week) is shorter than the first and / or second treatment period.
[0065] In some embodiments, the interferon lambda treatment comprises administering interferon lambda to the subject at a dose of 120 micrograms / week for a first treatment period, followed by administration of interferon lambda at a dose of 110-80 micrograms / week for a second treatment period. In some embodiments, the length of the first treatment period is the same as the length of the second treatment period. In some embodiments, the first treatment period and the second treatment period are of different duration. In some embodiments, the first treatment period (i.e., interferon lambda at a dose of 120 mcg / week) is longer than the second treatment period (i.e., interferon lambda at a dose of 80 mcg / week). In some embodiments, the second treatment period (i.e., interferon lambda at a dose of 80 mcg / week) is longer than the first treatment period (i.e., interferon lambda at a dose of 120 mcg / week).
[0066] In one embodiment, the interferon lambda therapy comprises administering a first dose of 180 micrograms of interferon lambda QW in a first treatment period, a second dose of 170-120 micrograms QE in a second treatment period, and a third dose of 110-80 micrograms QE in a third treatment period. In one embodiment, the first treatment period is at least 8 weeks, or 1-8 weeks, or 1-12 weeks in duration. In one embodiment, the first treatment period is 8-12 weeks in duration.
[0067] In one embodiment, interferon lambda therapy comprises administering a first dose of 160-180 micrograms / week of interferon lambda in a first treatment period, a second dose of 170-120 micrograms / week in a second treatment period, and a third dose of 110-60 micrograms / week in a third treatment period. In one embodiment, the first treatment period is at least 8 weeks, or 1-8 weeks, or 1-12 weeks in duration. In one embodiment, the first treatment period is 8-12 weeks in duration. Doses may be given in multiple doses per week, with the number of micrograms equivalent to the weekly dose.
[0068] In some embodiments, the treatment period (e.g., the first treatment period, the second treatment period, and / or the third treatment period) is at least 1 week in duration, e.g., at least 2 weeks, 3 weeks, 4 weeks, or longer. In some embodiments, the treatment period (e.g., the first treatment period, the second treatment period, and / or the third treatment period) is at least 2 weeks in duration, e.g., at least 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks, or longer. In some embodiments, the treatment period is at least 8 weeks in duration. In some embodiments, the treatment period is up to about 4 weeks in duration or up to about 6 weeks, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, or 48 weeks in duration. In some embodiments, the treatment period is up to about 8 weeks in duration. In one embodiment, the treatment period is for a period of up to about 12 weeks.
[0069] For subjects undergoing dose reduction, in some embodiments, a treatment period with a first dose is suspended or stopped prior to the start of a subsequent treatment period with a second, lower dose. For example, in some embodiments, a first treatment period (e.g., a dose of 180 mcg / week) is suspended or stopped at least 1 week, 2 weeks, 3 weeks, 4 weeks, or longer prior to the start of a second treatment period (e.g., a dose of 120 mcg / week).
[0070] In one embodiment, the subject is administered a first dose of 180 micrograms QW for at least 8 weeks prior to dose reduction.In one embodiment, the subject is administered a first dose of 180 micrograms QW for at least 8-12 weeks prior to dose reduction.
[0071] In one embodiment, the subject has a 3 ~<750 / mm 3 or ≧400 / mm 3 ~<650 / mm 3 or ≧400 / mm 3 ~<850 / mm 3 If the subject has an absolute neutrophil count (ANC) of 0.1 mg / kg / day, the subject begins the second treatment period.
[0072] In one embodiment, the subject has <500 / mm 3 If the subject has an ANC of >1000 / mm, then the subject to be administered 3 In another embodiment, dosing is discontinued for the subject until the subject has a pulmonary function of <400 / mm 2 and then dosing is resumed for a second treatment period. 3 If the subject has an ANC of >750 / mm 3 Dosing is discontinued to the subject until the patient is at least 60 days old, and then dosing is resumed for a second treatment period.
[0073] In some embodiments, if the subject has a platelet level <50,000, the subject begins a second treatment period or if the subject has a platelet level <25,000, the subject discontinues treatment.
[0074] In one embodiment, if a subject has a total bilirubin (TBILI)>2.5×upper normal range (ULN) and a direct bilirubin (DB)>3×ULN, administration to the subject is stopped until the subject has a TBILI≦1.5×ULN, and then administration is resumed for a second treatment period.
[0075] In one embodiment, if a subject has TBILI>3×ULN and DB>3×ULN, the subject is discontinued from dosing until TBILI≦1.5×ULN, and then administration is resumed for a second treatment period.
[0076] In one embodiment, if the subject has ALT (or AST) > 20 x ULN and TBILI and / or International Normalized Ratio (INR) < Grade 2, the subject's dosing is interrupted until ALT / AST < 10 x ULN, then dosing is resumed for a second treatment period. In one embodiment, if the subject has a second alanine aminotransferase (ALT) (or aspartate aminotransferase (AST)) > 20 x ULN and TBILI and / or INR < Grade 2, the subject's dosing is interrupted, then dosing is resumed for a second treatment period.
[0077] In one embodiment, if the subject has ALT (or AST) > 15-20 x ULN and TBILI and / or INR < Grade 2, the subject's dosing is interrupted until ALT / AST < 10 x ULN, then dosing is resumed for a second treatment period; or if the subject has a second ALT (or AST) > 15-20 x ULN and TBILI and / or INR < Grade 2, the subject's dosing is interrupted until ALT / AST < 10 x ULN, then dosing is resumed for a second treatment period.
[0078] In some embodiments, continued administration after discontinuation is resumed 1 week, 2 weeks, 3 weeks, or 4 weeks after discontinuation.
[0079] In one embodiment, if the subject has ALT (or AST) > 15 x ULN and TBILI and / or INR < Grade 2, the subject's dosing is interrupted until ALT / AST < 10 x ULN, then dosing is resumed for a second treatment period. In one embodiment, if the subject has ALT (or AST) > 15 x ULN and TBILI and / or INR < Grade 2 at the second ANC, then dosing is interrupted for the subject, then dosing is resumed for a second treatment period.
[0080] In one embodiment, if a subject has an ALT (or AST) > 5 x ULN and TBILI and / or INR > Grade 2, treatment of the subject is terminated.
[0081] In one embodiment, if a subject has an ALT (or AST) > 10 x ULN and TBILI and / or INR > Grade 3, treatment of the subject is terminated.
[0082] In one embodiment, if a subject experiences an adverse event > Grade 3, the subject is discontinued from dosing until the event resolves or < Grade 1, and dosing is resumed for a second treatment period.
[0083] In one embodiment, if the subject experiences a second adverse event of >= Grade 3, the subject's dosing is discontinued and then dosing is resumed for a third treatment period.
[0084] In one embodiment, treatment of a subject is discontinued if the subject has a creatinine clearance level of <50 mL / min.
[0085] In certain embodiments, subjects who meet criteria for treatment interruption, reduction and / or cessation based on hepatobiliary abnormalities may undergo a clinical workup including one or more of the following: autoimmune markers (antinuclear antibodies [ANA], anti-smooth muscle antibodies [e.g., anti-SMA], anti-LC1, anti-SLA liver-kidney microsomal type 1 and type III antibodies [e.g., anti-LKM1,3]); C3, C4 and CH50; acute viral hepatitis; acute hepatitis A and E serology (IgM); PCR (stool and blood) for HCV, hepatitis E; e.g., by PCR for cytomegalovirus (CMV), Epstein-Barr virus (EBV) or herpes simplex virus 1 and 2 (HSV); cholestatic workup with Doppler US of the liver; review of pre-existing liver disease (other than HBV); concomitant or herbal medications and hepatotoxicity. review for substances known to be harmful, alcohol and acetaminophen and drugs of abuse testing if necessary; liver ultrasound, including Doppler, should be performed for subjects with bilirubin levels >1.5x above baseline; liver biopsy should be performed if clinically feasible; if percutaneous biopsy is contraindicated, transjugular biopsy may be considered; liver and biochemistry tests should be performed weekly until bilirubin returns to baseline values (minimum including ALT, AST, bilirubin, INR, alkaline phosphatase and gamma-GT); HBV DNA and HDV RNA should be monitored weekly until Bili<1.5xULN; 5ml serum + 5ml plasma should be collected for possible later biomarker analysis.
[0086] In one embodiment, subjects with a 4-fold increase in baseline GGT, ALT / AST or alkaline phosphatase or Bili > 1.5 mg / dL, direct bilirubin > 0.6 (if Gilbert's syndrome is present) at any treatment period may be prescribed ursodeoxycholic acid for "liver protection".
[0087] In certain embodiments, the subject is also administered tenofovir DF or entecavir for the treatment of hepatitis B.
[0088] In one embodiment, for subjects with Stage 0-III disease, where the subject has ≦11.4 kPa at baseline, dose interruption, then reduction, then discontinuation is required sequentially as follows: for subjects with Alb>3.5 g / dL and INR<1.5 and total bilirubin<3 mg / dL, dose interruption 1 if ALT>20×ULN (>1000 IU / mL) and resume at the next lower lambda dose if ALT<10×ULN (<500 IU / mL) and dose interruption 2 if ALT 20×ULN (>1000 IU / mL) and then resume at the next lower lambda dose if ALT<10×ULN (<500 IU / mL) or discontinue if bilirubin is ≧3.0 mg / dL at the 80 mg dose.
[0089] The following abbreviations are used herein: AE, adverse event; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; DB, direct bilirubin; DILI, drug-induced liver injury; PT, prothrombin time; SAE, severe adverse event; TBILI, total bilirubin; ULN, upper limit of normal.
[0090] Treatment duration and treatment endpoints The subject may receive interferon lambda therapy for a defined period of time, an indefinite period of time, or until an endpoint is reached. Treatment may be continued continuously daily for at least 2-3 months. In some embodiments, treatment is for at least 30 days, at least 60 days, at least 90 days, at least 120 days, at least 150 days, or at least 180 days. In some embodiments, treatment is continued for at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 1 year, at least 15 months, at least 18 months, or at least 2 years. In some embodiments, treatment is for at least 6 weeks, 12 weeks, 18 weeks, 24 weeks, 30 weeks, 36 weeks, 42 weeks, 48 weeks, 60 weeks, 72 weeks, 84 weeks, or 96 weeks. In other embodiments, treatment is continued for the remainder of the subject's life or until administration is no longer effective in maintaining the virus at a sufficiently low level to provide a meaningful therapeutic benefit.
[0091] According to the methods herein, some HDV subjects respond to the treatments described herein by clearing the virus to undetectable levels. In one embodiment, for subjects with HDV RNA levels below detectable levels, treatment is discontinued unless or until HDV levels return to detectable levels. Other subjects experience viral load reduction and symptomatic improvement, but do not clear the virus to undetectable levels, but continue treatment for a defined period of time (e.g., about 1 year, about 2 years, about 3 years or more) or as long as therapeutic benefit is provided.
[0092] In one embodiment, treatment with interferon lambda therapy results in a decrease in inflammatory bowel disease in a subject of at least 1.5 log β-blocker inhibitors when measured after 8 weeks of treatment. 10 In one embodiment, treatment with interferon lambda therapy results in a reduction in HDV viral load in HDV RNA copies / mL serum. In one embodiment, treatment with interferon lambda therapy results in a reduction in HDV viral load of at least 2.0 log in a subject when measured after 48 weeks of treatment. 10In one embodiment, treatment with interferon lambda therapy results in a reduction in HDV viral load in HDV RNA copies / mL serum. In one embodiment, treatment with interferon lambda therapy results in a reduction in HDV viral load of at least 2.5 log in a subject when measured after 48 weeks of treatment. 10 Results in a reduction in HDV viral load of HDV RNA copies / mL serum.
[0093] In one embodiment, treatment with interferon lambda therapy results in a sustained reduction in HDV viral load (e.g., at least 1.5 log) that persists for a period of time (e.g., 1 month, 3 months, 6 months, 1 year or more) while the treatment course is still ongoing. 10 HDV RNAIU / mL serum, at least 2.0 log 10 HDV RNA copies / mL serum or at least 2.5 logs 10 In some embodiments, treatment with interferon lambda therapy results in a sustained reduction in HDV viral load that persists for a period of time (e.g., 1 month, 3 months, 6 months, 1 year or longer) after the course of treatment is completed. In some embodiments, the course of treatment results in an HDV RNA level (e.g., serum HDV RNA level or plasma HDV RNA level) of less than 1,000 copies / mL. In some embodiments, the HDV RNA level remains less than 1,000 copies / mL for at least 1 month, at least 3 months, at least 1 year or more. In some embodiments, the course of treatment results in an HDV RNA level (e.g., serum HDV RNA level or plasma HDV RNA level) of less than 100 copies / mL. The term "less than" refers to the viral load measurement remaining lower than the initial measurement (e.g., 100 copies / mL or 100 IU / mL) for a certain period of time, such as one month (or other specified period of time), after the determination of the initial measurement not higher than the initial value. In some embodiments, the subject does not receive interferon lambda therapy for a certain period of time. In some embodiments, the subject does not receive any anti-HDV treatment for a certain period of time.
[0094] In one embodiment, the treatments described herein reduce HDV RNA levels by 3 logs 10 Until HDV RNA copies / mL (<1,000 copies / mL) or HDV RNA levels drop by 2 log 10 The treatment is continued for a period of time until the HDV RNA copies / mL is less than (100 copies / mL) or below detection levels. In some embodiments, the treatment may be continued for a period of time (e.g., 1-3 months or more) after the viral load has fallen to an acceptably low level (e.g., undetectable). In some embodiments, the treatment is continued until the HDV viral load has fallen to undetectable levels.
[0095] In some embodiments, subjects treated according to the methods described herein exhibit a reduction in HDV viral load to undetectable levels during the course of treatment and maintain a reduced HDV viral load at undetectable levels for at least 12 weeks after treatment has ended. In some embodiments, subjects treated according to the methods described herein exhibit a reduction in HDV viral load to undetectable levels during the course of treatment and maintain a reduced HDV viral load at undetectable levels for at least 24 weeks after treatment has ended.
[0096] In certain embodiments, the subject's HDV titer rises from baseline during the course of treatment before dropping below baseline. In some embodiments, the subject's HDV levels rise to more than 150% above baseline, or more than 200% above baseline. In certain embodiments, the titer rise is 25-50% above baseline, or 25-100% above baseline, or 50-200% above baseline. In certain embodiments, the titer rise occurs within 2 weeks of initiating treatment. In certain embodiments, the subject's elevated HDV titer drops below baseline within 2 weeks or within 3 weeks of initiating treatment.
[0097] In some embodiments, the subject treated according to the methods described herein shows improvement in one or more liver function parameters.In some embodiments, the improvement in liver function is improvement in one or more serum markers (e.g., one, two, three, four, five, six or more markers), such as serum albumin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin, alpha2-macroglobulin, apolipoprotein A1, haptoglobin, gamma-glutamyl transpeptidase (GGT).In some embodiments, the subject treated according to the methods described herein shows improvement in liver fibrosis (e.g., assessed by histological analysis, biopsy by transient ultrasound elastography (e.g., FibroScan) or magnetic resonance elastography). In some embodiments, the treatment results in at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 70%, at least 75%, at least 80%, at least 100%, or 5-50% or 10-80% or 50-100% or greater improvement (e.g., improved serum markers or improved liver fibrosis) in one or more of the subject's liver function parameters compared to before treatment began. In some embodiments, the treatment results in an improvement in one or more liver function parameters (e.g., improved serum markers or improved liver fibrosis) to the level of a healthy control subject not infected with HDV or HBV. In some embodiments, the subject shows improvement in serum ALT levels to levels within the upper limit of normal.
[0098] In some embodiments, subjects treated according to the methods described herein exhibit a reduction in HBV viral load compared to baseline levels at the start of treatment and / or compared to similarly infected subjects who have not received a treatment effective to reduce the subject's HDV viral load. In some embodiments, treatment reduces HBV viral load by at least 1 log 10 This results in a reduction.
[0099] In some embodiments, subjects treated according to the methods described herein show improvement in one or more of the parameters described in Example 1. In some embodiments, subjects treated according to the methods of the invention show a reduction in HDV and / or HBV viral load. Prior to treatment, the subject's HDV and / or HBV viral load is measured to determine a baseline viral load. After a period of treatment (e.g., after 12 weeks of treatment), the subject's viral load is reduced compared to the baseline. In some embodiments, after a period of treatment (e.g., after 12 weeks of treatment), the subject's viral load is substantially reduced, such as to a very low level or to an undetectable level, compared to the baseline. In some embodiments, treatment results in at least a 2-log reduction in HBV viral load. 10 In one embodiment, subjects treated according to the methods described herein exhibit a reduction in HBsAg levels or improved clearance of HBsAg antigen. Prior to treatment, the subject's HBsAg levels are measured to determine a baseline. After a period of treatment (e.g., after 12 weeks of treatment), the subject's HBsAg levels are reduced compared to the baseline. In one embodiment, subjects treated according to the methods described herein exhibit the presence of anti-HBs antibodies.
[0100] In one embodiment, in a subject population treated with 180 μg interferon lambda, the response rate was high (>4 log 10 ) vs. low (≦4log 10 ) differ by subject's baseline viral load. In one embodiment, at week 48, 38-43% and 33-40% of subjects with high versus low baseline viral load, respectively, achieved HDV RNA levels at the BLQ. In another embodiment, at week 72, the difference between the two groups was more pronounced, with 50-60% of subjects with low baseline viral load reaching the BLQ versus 25-29% of subjects with high baseline viral load meeting this endpoint.
[0101] In one embodiment, the subject has about an 11% to about 14% chance of a treatment resulting in normalization of ALT levels, and about a 12.1% to about 42.4% chance. In another embodiment, the subject has a 15.1% to about 39.4% chance of a treatment resulting in BLQ HDV RNA. In another embodiment, the subject has a -1.18 log 10 HDV RNA~approx.-2.35log 10 A reduction in HDV RNA viral load is observed over 48 weeks of treatment. In one embodiment, subjects achieve ALT normalization and a >2 log reduction after the last dose compared to mid-treatment. 10 Reduction is likely to be achieved, in some cases with the last dose being between 4 and 48 weeks of dosing. In other embodiments, subjects achieve ALT normalization after 24 weeks of dosing in about 36-45% of subjects when dosed at 180 mcg / week. In some embodiments, the likelihood of subjects reducing to a second dose during treatment is about 26-36% of subjects; the rate of dose interruption is about 5-9% or treatment is discontinued at a rate of about 21-26%.
[0102] In one embodiment, the percentage of subjects receiving a 180 mcg / week dose have one or more of the following: dose reduction (about 30-36%), discontinuation (about 7-9%), and treatment discontinuation (about 21-24%). In another embodiment, the percentage of subjects receiving a 120 mcg / week dose have one or more of the following: dose reduction (about 26-30%), discontinuation (about 5-9%), and treatment discontinuation (about 24-26%). In another embodiment, subjects receiving a starting dose of 180 micrograms / week ... 10 Of subjects who had a baseline viral load of 180 micrograms / week, 38-43% of subjects achieved HDV RNA levels of BLQ at week 48. In other embodiments, of subjects who received a starting dose of 180 micrograms / week and had a high (>4 log) baseline viral load after the last dose, 25-29% of subjects who received a starting dose of 180 micrograms / week and had a low (≦4 log) baseline viral load after the last dose, achieved HDV RNA levels of BLQ at week 24 post-treatment. 10) baseline viral load achieved HDV RNA levels of the BLQ at week 48. In another embodiment, subjects receiving a starting dose of 180 micrograms / week achieved a low (≦4log) HDV RNA level after the last dose. 10 50-60% of subjects who had a baseline viral load of 180 micrograms / week achieved HDV RNA levels of BLQ at 24 weeks post-treatment. In another embodiment, subjects who received a starting dose of 180 micrograms / week achieved a high (>4log) HDV RNA level after the last dose. 10 ) baseline viral load achieved undetectable HDV RNA levels after 48 and 24 weeks of treatment. In another embodiment, subjects receiving a starting dose of 180 micrograms / week achieved low (≦4log) HDV RNA levels after the last dose. 10 ) 33-40% of subjects with a baseline viral load achieved undetectable HDV RNA levels after 48 and 24 weeks of treatment.
[0103] In other embodiments, after the last dose, 16-21% of subjects receiving a starting dose of 120 micrograms / week achieved HDV RNA levels of the BLQ; 21-29% of subjects receiving a starting dose of 120 micrograms / week achieved HDV RNA levels of >2log 10 11-14% of subjects receiving a starting dose of 120 micrograms / week achieved ALT normalization; 5-7% of subjects receiving a starting dose of 120 micrograms / week achieved ALT normalization +>2 10 In another embodiment, 24 weeks after the last dose, 16-21% of subjects receiving a starting dose of 180 micrograms / week achieved HDV RNA levels at the BLQ; 11-14% of subjects receiving a starting dose of 180 micrograms / week achieved HDV RNA levels at the BLQ >2log 10 26-36% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization; 11-14% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization +>2 log 10In another embodiment, after the last dose, 36-45% of subjects receiving a starting dose of 180 micrograms / week achieved HDV RNA levels at the BLQ; 50-64% of subjects receiving a starting dose of 180 micrograms / week achieved a >2 log reduction; 14-18% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization; 4-18% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization + >2 log reduction. 10 In another embodiment, 24 weeks after the last dose, 36-45% of subjects receiving a starting dose of 180 micrograms / week achieved HDV RNA levels of the BLQ; 10 36-45% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization; 29-36% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization +>2 10 At least one of the following was true: reduction was achieved;
[0104] Antiviral co-treatment In certain embodiments, subjects receiving interferon lambda therapy according to the present invention may also be treated with one or more other antiviral agents, such as nucleoside and nucleotide analogs, compounds used to treat HBV infection, and other medications.
[0105] In one embodiment, the subject receiving interferon lambda therapy is treated with an antiviral agent used to treat HBV. Other than interferon, currently approved anti-HBV drugs inhibit reverse transcriptase and are nucleoside or nucleotide analogs. These drugs are effective against HBV, but are not effective against HDV because they do not remove HBsAg, which HDV requires for replication. Currently approved anti-HBV nucleoside / nucleotide analogs include lamivudine (Epivir-HBV®, Zeffix® or Heptodin®), adefovir dipivoxil (Hepsera®), entecavir (Baraclude®), telbivudine (Tyzeka® or Sebivo®), clevudine (Korea / Asia), tenofovir (Viread® or Vemlidy®). In some embodiments, the subject receiving interferon lambda therapy is also administered a nucleoside or nucleotide analog, such as, but not limited to, lamivudine, adefovir, telbivudine, entecavir, tenofovir, or clevudine. In some embodiments, the subject receives the nucleoside or nucleotide analog treatment prior to the initiation of interferon lambda therapy. In some embodiments, the nucleoside or nucleotide analog treatment is initiated at the initiation of interferon lambda therapy or during the course of interferon lambda therapy.
[0106] In one embodiment, the subject receiving interferon lambda therapy is treated with lonafarnib. Lonafarnib therapy for the treatment of HDV is disclosed in US2017 / 0042862, which is incorporated herein by reference. In one embodiment, the subject receiving interferon lambda therapy also receives lonafarnib therapy at a total daily dose of 50-200 mg / day, e.g., 50 mg / day, 75 mg / day, 100 mg / day, 150 mg / day or 200 mg / day. The lonafarnib therapy may be administered once a day (QD) or twice a day (BID). In one embodiment, the subject receiving interferon lambda therapy also receives lonafarnib therapy at a dose of 25 mg BID, 50 mg BID, 75 mg BID, 100 mg BID, 50 mg QD, 75 mg QD or 100 mg QD. In some embodiments, lonafarnib treatment is initiated at the start of interferon-lambda treatment or during the course of interferon-lambda treatment.
[0107] In one embodiment, the subject receiving interferon lambda therapy is treated with lonafarnib and a CYP3A inhibitor co-therapy, such as ritonavir or cobicistat. In one embodiment, the CYP3A inhibitor is ritonavir.Lonafarnib and ritonavir co-therapy are disclosed in WO2015 / 168648 and WO2017 / 079009, which are incorporated herein by reference. In one embodiment, the subject receiving interferon lambda therapy also receives lonafarnib-ritonavir co-therapy at a total daily dose of 50-200 mg of lonafarnib per day (e.g., 50 mg / day, 75 mg / day, 100 mg / day, 150 mg / day, or 200 mg / day of lonafarnib) and 100-200 mg of ritonavir per day (e.g., 100 mg / day, 150 mg / day, or 200 mg / day of ritonavir). The lonafarnib-ritonavir co-therapy may be administered once daily (QD) or twice daily (BID). In one embodiment, a subject receiving interferon lambda therapy is also administered lonafarnib at a dose of 25 mg BID, 50 mg BID, 75 mg BID, 100 mg BID, 50 mg QD, 75 mg QD, or 100 mg QD and ritonavir at a dose of 50 mg BID or 100 mg BID. In one embodiment, lonafarnib-ritonavir co-therapy is initiated at the start of interferon lambda therapy or during the course of interferon lambda therapy.
[0108] Other therapeutic compounds that have beneficial effects and may be administered to HDV-infected subjects receiving interferon lambda therapy include thiazolides; protease inhibitors; polymerase inhibitors; helicase inhibitors; class C CpG Toll-like receptor 7 and / or 9 antagonists; amphipathic helix breakers or NS4B inhibitors; statins or other HMG CoA reductase inhibitors; immunomodulators; anti-inflammatory agents; second prenylation inhibitors; cyclophilin inhibitors; and alpha-glucosidase inhibitors.
[0109] In various embodiments, interferon lambda is administered in combination with standard nucleoside HBV drugs and promising new anti-HDV therapies described in US2017 / 0042862, such as lonafarnib therapy, optionally with potentiators such as ritonavir for optimal therapeutic efficacy. When administered in combination with other anti-HBV or HDV medications, physicians may initiate administration of interferon lambda in accordance with the present invention at any daily dose in the general range of 80-180 mcg, for example, at a starting dose of 180 mcg / day, 120 mcg / day, or 80 mcg / day. Some subjects in Pakistan have shown unwanted side effects (high bilirubin levels) with interferon lambda therapy described herein, possibly due to genetic mutations in genes affecting bilirubin transport, and physicians have adopted to first implement other treatment regimens, and in any case such subjects are closely monitored for the appearance of such side effects to ensure that dosing is discontinued or reduced to eliminate them.
[0110] Formulation and Administration Interferon lambda may be formulated for administration by any suitable route for treatment. In some embodiments, interferon lambda is formulated for administration by intravenous or subcutaneous administration. Other routes suitable for drug delivery may be used, including systemic and local administration routes.
[0111] In one embodiment, interferon lambda is administered subcutaneously (eg, by subcutaneous injection). Injection sites include, but are not limited to, injection into the thigh, abdomen, upper arm region, or upper gluteal region.
[0112] In some embodiments, interferon lambda (e.g., pegylated interferon lambda) is formulated as a pharmaceutical formulation comprising interferon lambda and one or more additives, such as a preservative, a surfactant (e.g., polysorbate or poloxamer), or a coloring agent (e.g., pharma- ceutically acceptable dyes, inorganic dyes, and natural colors). A variety of pharma-ceutically acceptable additives are known in the art. Pharmaceutically acceptable excipients are widely described in a variety of publications, including, for example, A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy," 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) HC Ansel et al., eds., 7th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) AH Kibbe et al., eds., 3rd ed. Amer. Pharmaceutical Assoc., each of which is incorporated herein by reference.
[0113] In some embodiments, interferon lambda may be formulated into an injectable formulation by dissolving, suspending or emulsifying interferon lambda in an aqueous or non-aqueous solvent, such as vegetable oil or other similar oil, synthetic aliphatic acid glyceride, ester of higher aliphatic acid, or propylene glycol, optionally with conventional additives such as solubilizers, isotonicity agents, suspending agents, emulsifiers, stabilizers and preservatives. Unit dosage forms for injection or intravenous administration may include the composition as a solution in sterile water, saline or other pharma- ceutically acceptable carrier. Suitable amounts of active pharmaceutical ingredient for unit dosage forms of interferon lambda are provided herein.
[0114] In one embodiment, interferon lambda (e.g., interferon lambda 1, such as interferon lambda 1a) or an analog thereof is formulated and / or administered and / or modified as described in one of the following patent publications: U.S. Patents 6,927,040, 7,038,032, 7,135,170, 7,157,559 and 8,980,245, US2009 / 0326204, US2010 / 0222266, US2011 / 0172170 or US2012 / 0036590, which are incorporated by reference herein. EXAMPLES
[0115] III. Working Examples The following examples are offered to illustrate, but not to limit, the present invention.
[0116] Example 1. Clinical Trial Protocol for Treating HDV Subjects with Pegylated Interferon Lambda This example describes a Phase 2 clinical trial protocol to evaluate the safety, tolerability, and pharmacodynamics of pegylated interferon lambda monotherapy in subjects with chronic HDV infection. [Table 1-1] [Table 1-2]
[0117] At least one subject from a cohort of subjects receiving at least 80% of the total study drug dose throughout the entire 48-week treatment period and with HDV viral load data available at Day 1 (baseline) and end-of-treatment (week 48) study visits shows improvement in one or more endpoints described in the protocol. In some embodiments, the subject shows a reduction in end-of-treatment HDV viral load compared to baseline. In some embodiments, the subject shows a reduction in end-of-treatment HBV viral load compared to baseline. In some embodiments, the interferon lambda treatment shows a substantial reduction in HDV virus, such as undetectable levels measured 12 weeks after the end of treatment. In some embodiments, the subject shows a reduction in end-of-treatment HBsAg levels compared to baseline. In some embodiments, the subject shows improvement in HBsAg antigen clearance. In some embodiments, the subject shows a reduction in alanine aminotransferase (ALT) levels. In some embodiments, subjects with serum ALT above the upper limit of normal (ULN) before treatment initiation show improvement in serum ALT levels to a level within the ULN.
[0118] Example 2. Pegylated Interferon Lambda Monotherapy for HDV Treatment This example describes interim data through 24 weeks of a Phase 2 pegylated interferon lambda-1a (LIMT) clinical trial conducted according to the protocol described in Example 1.
[0119] Background: 15-20 million people worldwide are co-infected with hepatitis delta (HDV) and hepatitis B (HBV) viruses. Interferon (IFN) or pegylated (PEG) IFN-alpha has been tested in subjects with chronic HDV. Up to 25% of subjects can become HDV PCR negative, but the majority relapse after treatment cessation and the tolerability profile is unsatisfactory. PEG IFN lambda-1a ("Lambda") is a type III IFN. Due to Lambda's lesser receptor distribution, it was hypothesized that Lambda would induce an HDV response but with fewer side effects than IFN-alpha. LIMT HDV is the first clinical trial of Lambda in subjects with chronic HDV infection, including incuration.
[0120] Randomized, open-label trial of Lambda 120 μg or 180 μg administered by subcutaneous injection weekly for 48 weeks in subjects with chronic HDV. Main inclusion criteria were positive HDV RNA by qPCR, elevated ALT <10×ULN, compensated liver disease and platelets ≥90,000 cells / μL. HDV RNA (Robogene 2.0, LLOQ 14 IU / mL), ALT, bilirubin and other parameters were assessed at each visit. Tenofovir or entecavir was initiated at baseline (BL) and continued until the end of the study. The primary endpoint was change from baseline in HDV viral load.
[0121] A total of 33 subjects were enrolled. Subcutaneous injections of Lambda (120 μg or 180 μg) were administered weekly for 48 weeks to subjects with chronic HDV. Sixteen subjects were randomized to Lambda 180 μg / week and 17 subjects were randomized to Lambda 120 μg / week. Subject baseline median characteristics are shown in Table 2 below. Due to an increased frequency of liver-related SAEs in Karachi district, Pakistan (observed in 7 / 15 [46.7%] subjects), all 6 subjects randomized to 180 mcg / week in Karachi district were reduced to 120 mcg / week (before first dose). As a result of this change in dosing regimen, for the efficacy and safety evaluations presented here, subjects are categorized by starting Lambda dose rather than randomized treatment group: 14 / 33 subjects on Lambda 180 mcg ("180 dose") and 19 / 33 subjects on Lambda 120 mcg ("120 dose"). [Table 2] 1 ALT normal range: 10-35U / ml (female); 10-50U / ml (male) 2 Normal bilirubin range: 0-1.2mg / dL
[0122] At the time of the interim analysis, all subjects had reached at least week 4 of treatment, with some reaching week 8, 12, or 24 of treatment. Figure 1 shows that subjects treated with interferon lambda showed rapid reduction in HDV RNA. As shown in Table 3 below, of subjects who had reached week 24 of treatment, 50% achieved a HDV RNA reduction of ≥ 2.0. 40% of subjects were HDV PCR negative. Mild to moderate headache, fever, fatigue, and myalgia were the most commonly reported AEs. Protocol-driven dose reductions (12%), interruptions (12%), and treatment discontinuations (15%) were primarily due to hepatic AEs (ALT flare and / or hyperbilirubinemia). ALT flare and liver function abnormalities generally correlated with HDV viral load reduction. No instances of clinical decompensation were observed. [Table 3]
[0123] This interim analysis shows that weekly Lambda - 120 μg or 180 μg - has antiviral activity against HDV, with some subjects becoming PCR negative already at week 8 of treatment. Lambda shows anti-HDV activity comparable to classical PEG-alpha at week 24 of treatment. Moreover, Lambda treatment was well tolerated by the majority of subjects.
[0124] Example 3. Pegylated Interferon Lambda Monotherapy for HDV Treatment This example describes end-of-treatment data at week 48 of the Phase 2 pegylated interferon lambda-1a (LIMT) clinical trial described in Examples 1 and 2. Methods and subject baseline characteristics are as described in Example 2 and Table 2 above.
[0125] Twenty-three of 33 subjects reached week 48 (end of treatment) and 10 subjects discontinued treatment. As shown in Figure 2, subjects treated with interferon lambda demonstrated rapid reductions in HDV RNA. Twenty of 33 subjects (60.6%) achieved a ≥ 2 log reduction in HDV RNA at week 48. 10Responders were defined as reduced or HDV RNA below the limit of quantification or below the limit of detection (BLQ / BLD). For BLQ, the limit of quantification was 14 IU / mL. For BLD, the limit of detection was 8 IU / mL. HDV RNA data are also shown in Table 4 below. The anti-HDV activity of interferon lambda is comparable to the classical data of pegylated interferon-alpha. [Table 4] * BLQ = less than limit of quantification (14 IU / mL); BLD = less than limit of detection (8 IU / mL)
[0126] As shown in Figure 3, subjects treated with the 180mcg Lambda dose demonstrated a higher response rate than subjects treated with the 120mcg Lambda dose, despite protocol dose reduction. For subjects treated with 180mcg interferon lambda, the response rate was -2.35log at week 48. 10 There was a mean reduction in HDV RNA compared to -1.18 log for subjects treated with 120 mcg interferon lambda. 10 HDV RNA was ≥ 2 log in the 180 mcg treatment group. 10 A higher number of subjects showed a reduction (6 subjects, 37.5%) in HDV RNA BLD / BLQ (5 subjects, 31.2%). In summary, interferon lambda treatment is well tolerated and exhibits anti-HDV activity comparable to pegylated interferon alpha.
[0127] Example 4. End-of-Study Results from the LIMT HDV Trial: 36% Sustained Virologic Response After 24 Weeks of Treatment with Pegylated Interferon Lambda Monotherapy in Subjects with Chronic Hepatitis Delta Virus Infection Background: Hepatitis Delta Virus (HDV) infection leads to the most aggressive form of human viral hepatitis. There is no approved treatment. The global prevalence of HDV infection is 15-20 million. PEG IFN-lambda-1a (Lambda) has previously demonstrated a good tolerability profile in >3000 HBV and HCV subjects, with fewer cytopenias, flu-like symptoms, and psychiatric symptoms compared to PEG IFN-alpha (Alpha). This clinical trial, LIMT, was designed to evaluate the safety and efficacy of interferon lambda monotherapy ("Lambda") in subjects with HDV.
[0128] This was a randomized, open-label trial of weekly SC injections of Lambda 120 μg or 180 μg for 48 weeks, followed by 24 weeks post-treatment in subjects with chronic HDV.
[0129] Inclusion criteria were positive HDV RNA by qPCR (Robogene® 2.0, BLQ 14 IU / mL), ALT < 10 × ULN and compensated liver disease. Tenofovir or entecavir was started at baseline (BL).
[0130] In this trial, 33 subjects were randomized to receive Lambda 180 μg (N=14) or 120 μg (N=19). Mean BL: HDV RNA 4.1 log 10 IU / mL (SD ± 1.4);ALT 106 IU / L (35-364) and bilirubin 0.5 mg / dL (0.2-1.2).See Table 5 below. [Table 5] * Low baseline viral load = HDV RNA ≤ 4log 10 IU / mL ** The starting dose *** All subjects who completed the study and did not discontinue treatment
[0131] At week 48, 36% to 45% of subjects in the Lambda 180mcg group had HDV RNA levels below the LLOQ (BLQ). The proportion of these subjects with HDV RNA levels BLQ was similar in those with high versus low viral load at baseline (38% [3 / 8] and 33% [2 / 6], respectively) (Table 5).
[0132] At 24 weeks post-treatment, BLQ remained similar to EOT in the Lambda 180 mcg group (36–45%) and was overall similar to EOT results among those with high versus low viral load at baseline (25% [2 / 8] and 50% [3 / 6], respectively) (Table 5).
[0133] Following Lambda 180 mcg / week treatment, 29-36% of subjects (4 / 14 total subjects, 4 / 11 completers) were reported to have undetectable HDV RNA at week 48 and 24 weeks post-dose (Table 8), further demonstrating the durability of Lambda's viral response.
[0134] The ITT rate of sustained virologic response (DVR = BLQ after 24 weeks of treatment) with Lambda 180 μg (5 of 14, 36%) was favorable versus the historical rate of undetectability with Alpha 180 μg (0%) (Wedemeyer, 2019). 10 ) was shown to have a 50% DVR with Lambda 180mcg QW.
[0135] Common treatment-emergent AEs included mild to moderate flu-like symptoms and elevated aminotransferase levels. Subjects previously treated with Alpha showed significantly fewer side effects with Lambda. An increased incidence of jaundice cases and bilirubin elevations was noted in the Pakistani cohort. No subjects showed symptoms of decompensation and all responded well to dose reduction or dose interruption. DILIsym® modeling of ALT and bilirubin kinetics indicates a transporter-based mechanism for the observed bilirubin elevations.
[0136] Lambda 180μg had good antiviral activity with good tolerability compared to classical data for alpha 180mcg. A sustained BLQ viral response was observed after 24 weeks of treatment with Lambda 180mcg.
[0137] Figure 4 shows the sustained virologic response (DVR) after 24 weeks (72 weeks) of treatment with both Lambda180 and 120mcg QW. A sustained virologic response (DVR) was defined as the 24-week post-treatment response of HDV RNA BLQ. The 2 log 10 A reduction can be considered a clinically meaningful reduction in HDV viral load that may result in improved survival (Farci et al 2004). PEG IFN alpha demonstrated that 23% of patients had undetectable HDV RNA at 48 weeks and 0% of patients had undetectable HDV RNA after 24 weeks of treatment.
[0138] Surprisingly, what is shown here is that treatment with Lambda improves the sustainable response rate by about 36-45%, better than the about 25% response obtained with Alpha. Figure 9 and Table 6 further show that 36-45% of subjects treated with Lambda who achieved BLQ after 48 weeks of treatment maintained HDV RNA BLQ after 24 weeks of treatment.
[0139] Among subjects in the Lambda 180 mcg / week group, 50-64% had a HDV RNA decrease >2 log from baseline at week 48 10 At 24 weeks after the final dose, 36-45% had a clinically meaningful reduction in HDV RNA >2log from baseline 10 The results showed a reduction in the IL-10 binding capacity (Figure 9 and Table 6).
[0140] In subjects treated with Lambda 120 mcg / week, response rates at EOT and 24 weeks after the last dose were lower than those seen in the 180 mcg / week group. However, response rates at EOT remained similar at washout follow-up. At week 72, 16-21% (3 / 19) of subjects in the 120 mcg / week group demonstrated HDV RNA BLQ, and 11-14% (2 / 19) demonstrated a HDV RNA increase >2 log from baseline. 10 The results showed a reduction in the IL-10 binding capacity (Figure 9 and Table 6).
[0141] At week 48, 14-18% and 11-14% of subjects treated with the 180mcg / week and 120mcg / week doses of Lambda, respectively, demonstrated ALT normalization. At 24 weeks after the last dose, these figures improved to 36-45% and 26-36%, respectively.
[0142] The majority of protocol dose reductions (26-36% of subjects), interruptions (3-15% of subjects) and treatment discontinuations (21-26% of subjects) were due to hepatobiliary laboratory abnormalities (elevated ALT, AST, GGT and / or bilirubin). Of the 8 (24.2%) subjects who discontinued study drug treatment, 5 (62.5%) were from Karachi, Pakistan, and pharmacogenomic and / or environmental factors may have contributed. No cases of clinical decompensation were observed. The percentages in brackets of subjects receiving the 180 mcg / week dose showed one or more of the following: dose reductions (approximately 12-35%), interruptions (approximately 7-15%) and treatment discontinuations (approximately 15-21%).
[0143] The percentages shown in parentheses of subjects receiving the 120 mcg / week dose showed one or more of the following: dose reduction (approximately 12-35%), interruption (approximately 7-15%), and treatment discontinuation (approximately 15-21%).
[0144] FIG. 10 and Table 6 show that subjects achieved ALT normalization and ≧2 log 10The composite endpoint of ALT normalization and reduction of > 2 log from baseline was achieved, which is also clinically meaningful. Furthermore, the proportion of subjects achieving the composite endpoint increased even after treatment was stopped, demonstrating a surprising finding of benefit of HDV treatment with Lambda. 10 When combining HDV RNA response defined as viral load reduction or HDV RNA BLQ, 14-18% of subjects achieved a combined response at week 48 and 29-36% of subjects at week 72 in the Lambda 180mcg / week group. For the Lambda 120mcg / week group, the combined response rates at week 48 and week 72 were 5-7% and 11-14%, respectively. Some subjects experienced an ALT flare (e.g., a transient increase) from baseline measurement, where a flare is 4x from baseline, end-of-treatment measurement, or 1 or more above the upper limit of normal. In this trial, approximately 24-32% of subjects had an ALT flare from baseline measurement. 12-16% of subjects had a flare as measured from end-of-treatment. Of all subjects who experienced a flare, 44-92% of subjects experienced ALT normalization after the flare as measured from baseline or end-of-treatment measurement at week 48. In one embodiment, the transient ALT increase is greater than about 300-1100% above previous levels or baseline. [Table 6] Starting dose. Due to an increased frequency of liver-related SAEs in Karachi, Pakistan (observed in 7 / 15 [46.7%] subjects), all 6 subjects randomized to 180 mcg / week in Karachi were reduced to 120 mcg / week (if possible before first dose). As a result of this change in dosing regimen, for efficacy and safety evaluations presented in this preliminary report, subjects are categorized by starting Lambda dose rather than randomized treatment group: 14 / 33 subjects at Lambda 180 mcg and 19 / 33 subjects at Lambda 120 mcg. * Starting Dose ** All subjects in the clinical trial *** All subjects who completed the study and did not discontinue treatment
[0145] In the Lambda 180 μg treatment group, the response rate was high (>4 log 10 ) vs. low (≦4log 10 ) differed between baseline viral loads. At week 48, 38-43% and 33-40% of subjects with high versus low baseline viral loads, respectively, reached HDV RNA levels at the BLQ. At week 72, the differences between these two groups became more pronounced, with 50-60% of subjects with low baseline viral loads reaching the BLQ compared with 25-29% of those with high baseline viral loads meeting this endpoint (Table 6).
[0146] At week 48, 25–29% and 33–40% of subjects with high versus low baseline viral loads, respectively, achieved undetectable HDV RNA levels. At week 72, the difference between these two groups was consistent with the week 48 measurement, with 33–40% of subjects with low baseline viral loads reaching the BLQ compared with 25–29% of those with high baseline viral loads meeting this endpoint (Table 6).
[0147] Maintenance of this response after treatment may indicate that the subject's immune response has gained control of viral replication. Surprisingly, the high percentage of patients with undetectable HDV RNA after 24 weeks of treatment (29%) with Lambda 180mcg QW was observed to be comparable to that reported in a previous HDV trial with pegylated interferon alpha-2a (0% in the Myr203 trial).
[0148] Figure 5 shows ALT normalization with Lambda. Alanine aminotransferase (ALT) normalization is a sign of improved liver health. ALT normalization was observed in 14% and 11% of Lambda 180mcg QW and Lambda 120mcg QW treated subjects, respectively, at the end of treatment. ALT normalization continued to increase after 24 weeks of treatment (week 72).
[0149] Figures 4 and 6 and Tables 7 and 8 show that Lambda 180mcg QW results in greater HDV RNA reduction compared to the Lambda 120mcg QW dose despite dose reductions during treatment (180mcg to 120mcg or 120mcg to 80mcg). [Table 7] * Starting dose. Due to an increased frequency of liver-related SAEs in Karachi district, Pakistan (observed in 7 / 15 subjects), all 6 subjects randomized to 180 mcg / week in Karachi district were reduced to 120 mcg / week (if possible before first dose). As a result of this change in dosing regimen, for efficacy and safety evaluations presented in this lead report, subjects are categorized by starting Lambda dose rather than randomized treatment group: 14 / 33 subjects at Lambda 180 mcg and 19 / 33 subjects at Lambda 120 mcg. ** All subjects in the clinical trial *** All subjects who completed the study and did not discontinue treatment
[0150] Figure 7 shows that Lambda treatment reduced HBsAg by >1log in some subjects. 10 The results show that HBsAg levels continue to decrease after treatment in some subjects. Low HBsAg levels may reflect HBeAg loss and HBV infectivity.
[0151] Figure 8 shows the HDV RNA of responders at week 48 of treatment. Responders had HDV RNA reduction > 2 Log at week 48. 10 or defined as below limit of quantification (BLQ).
[0152] Table 8 shows the disposition of subjects on the trial. For example, 19 subjects started on the 120mcg dose and 14 on the 180mcg dose. However, 14 subjects remain on the 120mcg dose throughout the 72-week trial, and 11 on the 180mcg dose. Here, some data is calculated by the number of subjects enrolled and started (primary analysis population) (shown as "N" in Table 8) and some data is calculated by reference to the "stay-in-trial population" (per protocol) numbers in Table 8. [Table 8] * Starting dose (as indicated)
[0153] Table 9 shows that with Lambda treatment in this trial, flu-like symptoms and psychiatric symptoms were predominantly grade 1. Cytopenias and thrombocytopenia (but not thrombocytopenia) were much less frequent compared to classical pegylated interferon alpha use. Flu-like symptoms and psychiatric symptoms were mild and infrequent with Lambda in this trial, and there was no thrombocytopenia. There were elevated bilirubin and ALT levels that normalized with dose reduction or treatment discontinuation. [Table 9] a Flu-like symptoms: fever, cough, sore throat, runny / stuffy nose, muscle / joint pain, headache, weakness, vomiting, diarrhea b Psychiatric symptoms: depression, irritability, insomnia c Eleven of the 18 events occurred in four subjects in the Pakistan region. d Laboratory values normalized with dose reduction or treatment cessation [Table 10]
[0154] Table 10 shows that in this trial, there were milder flu-like and psychiatric symptoms with Lambda compared to the previous trial with Alpha. There were no thrombocytopenic events, no hematopoietic factor use, and elevated bilirubin and ALT levels normalized with dose reduction or treatment discontinuation. In a head-to-head study of Lambda versus Alpha in a Phase 2 trial of 176 HBV-infected subjects (LIRA-B), the overall frequency of clinically notable events (constitutional symptoms, neurological events, flu-like symptoms, musculoskeletal symptoms, and psychiatric events) was higher in the Alpha group (72.3%) than in the Lambda 180 μg group (50.0%).
[0155] Laboratory abnormalities were consistent with the known safety profile of Lambda and Alpha, with increased frequency of ALT, AST, and bilirubin (grades 1-4 and grades 3 / 4) in the Lambda 180 μg group compared with the Alpha group; and increased frequency of cytopenias, especially leukopenia, neutropenia, and thrombocytopenia (grades 1-4), in the Alpha group compared with the Lambda 180 μg group. Flu-like and psychiatric symptoms observed with Lambda were milder and less frequent when compared with other interferons such as Alpha. No events of thrombocytopenia were reported, and no hematopoietic factors were used. All occurrences of elevated bilirubin, ALT, and / or AST levels normalized after dose reduction or treatment cessation.
[0156] Adverse events reported in subjects receiving Lambda 180mcg / week were more severe for constitutional (fatigue, asthenia) and neurologic (dizziness, headache) AEs, but less severe for laboratory abnormalities (increased bilirubin, ALT, AST, GGT, or INR; DILI; decreased blood albumin; abnormal LFTs) compared to those receiving Lambda 120mcg / week. See Tables 11 and 12. [Table 11] Abbreviations: AE = adverse events; ALT = alanine aminotransferase; AST = aspartate aminotransferase; DILI = drug-induced liver injury; GGT = gamma-glutamyltransferase; INR = international normalized ratio; LFT = liver function tests. [Table 12] Abbreviations: AE = adverse events; ALT = alanine aminotransferase; AST = aspartate aminotransferase; DILI = drug-induced liver injury; GGT = gamma-glutamyltransferase; INR = international normalized ratio; LFT = liver function tests.
[0157] In this study, the incidence of hyperbilirubinemia was higher in the Pakistani cohort. For example, the following parameters differed from the other cohorts: hyperbilirubinemia in 4 / 15 (27%) Pakistanis vs. 2 / 18 (11%) in the non-Pakistani cohort; jaundice observed in 3 / 15 (20%) Pakistani subjects vs. 0 / 18 (0%) in the non-Pakistani cohort; incidence / severity in the non-Pakistani cohort is consistent with previous Lambda and Alpha data in HBV. That is, subjects with elevated bilirubin did not show signs or symptoms of decompensation, bilirubin levels responded to dose reduction / interruption, and subjects had normal liver function (PT) during elevated bilirubin.
[0158] In summary, in the 24 subjects who reached 48 weeks: 120 μg group (N = 14) had a mean HDV RNA reduction of 1.5 log 10 6 of 14 had ≥ 2 log 10 reduction (42.9%); 180 μg group (N=10) had a mean HDV RNA reduction of 2.4 log 10 and 6 out of 10 had ≥ 2 log 10Lambda was generally well tolerated, with increased incidence of clinical jaundice and elevated bilirubin observed in the Pakistani cohort. This resulted in a lower than expected study completion rate in the Pakistani region (9 of 15, 60%), however none of the subjects with elevated bilirubin developed symptoms of decompensation. All responded favorably to dose reduction or interruption.
[0159] The 180mcg / week Lambda dose provided greater efficacy than the 120mcg / week Lambda dose despite dose interruptions or reductions or discontinuations during treatment. Approximately 35-45% of subjects on the 180mcg / week dose reduced to a 120mg dose. Approximately 7-9% of subjects on the 180mcg / week dose reduced their dose twice.
[0160] After 48 weeks of Lambda 180 mcg / week treatment, 36-45% of subjects achieved HDV RNA levels BLQ (29-36% undetectable) and 50% achieved a HDV RNA increase >2 log from baseline. 10 A reduction was observed.
[0161] Twenty-four weeks after dosing (e.g., after the final or last dose), this virologic response was maintained, with 36-45% of subjects demonstrating HDV RNA levels BLQ (29% undetectable) on Lambda 180 mcg / week treatment.
[0162] In comparison, a recent trial using the same RoboGene assay (Kit 2.0) to measure HDV RNA for efficacy of Myrcludex B and PEG-IFNα combination in subjects with chronic HBV / HDV coinfection reported that 13% (2 / 15) of subjects had undetectable HDV RNA at week 48 and 0% after 24 weeks of treatment (week 72) (Wedemeyer et al., 2019), ILC 2019;GS-13
[0163] Among subjects in the Lambda 180mcg / week group, 36-45% reported ALT normalization after 24 weeks of treatment, a trend observed in previous studies with Lambda in subjects with HBV and HCV, presumably related to the immunomodulatory effects of Lambda on host effector cells, resulting in a transient increase in ALT during treatment followed by normalization after treatment. Additionally, at the 180mcg / week dose, 29-36% of subjects achieved ALT normalization and HDV RNA BLQ or >2log from baseline. 10 A reduction in either of the composite response criteria was met.
[0164] At week 48, 7 of 33 subjects had a 1-log increase from the previous measurement of HDV RNA level during the 48-week period. 10 Rebounded with an increase of > 180 mcg. None of the 7 rebound subjects were found to meet the BLQ at the end of 48 weeks. 21% of rebound subjects were non-responders. 29% of rebound subjects initiated on the 180 mcg dose.
[0165] Lambda PK has been characterized after single and multiple SC administration of Lambda in healthy subjects and patients with HCV (Table 12). Median time to maximum concentration (Tmax) ranged from 8.00 to 25.1 hours (range, 1 to 120 hours). After a single dose of Lambda 180 μg, geometric mean maximum observed concentration (Cmax) (coefficient of variation [%CV]) values ranged from 1.06 (102) to 2.41 (177) ng / mL. After multiple doses, the geometric mean Cmax (%CV) was 1.54 (86.0) ng / mL, indicating moderate accumulation. Areas under the concentration-time curve (AUCinf) extrapolated from time 0 to infinity (%CV) after single SC administration of Lambda 180 μg to healthy subjects and patients with HCV ranged from 116.9 (73.1) to 221 (59) ng×hour / mL. In general, exposure values (area under the concentration-time curve [AUC] and Cmax) were approximately dose-proportional over the 80-240 μg dose range. Mean (standard deviation [SD]) elimination half-lives (T1 / 2) ranged from 50.43 (20.47) to 74.0 (42.7) hours. [Table 13]
[0166] Population PK modeling showed that body weight affected clearance, consistent with standard relative growth; however, while body weight significantly affected clearance, the effect was small compared to the overall intersubject variability, and therefore does not justify weight-based dosing. Preliminary results indicate that renal impairment increases exposure; Cmax and AUC were approximately 13% and 20% greater, respectively, in subjects with mild impairment compared to subjects with normal renal function, and approximately 2-fold greater across the moderate renal insufficiency, severe renal insufficiency, and end-stage renal disease (ESRD) groups. Preliminary clinical results suggest that after a single 180 μg dose, Lambda is a mild inhibitor of CYP1A2, CYP2C9, and CYP3A4, and a moderate inhibitor of CYP2C19 and CYP2D6.
[0167] All publications and patents cited in this specification are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference, and are herein incorporated by reference to disclose and describe the methods and / or materials in which the publications are cited.
[0168] While the present invention is specifically disclosed by certain aspects, embodiments and optional features, it should be understood that modifications, improvements and variations of such aspects, embodiments and optional features may be made by those skilled in the art, and such modifications, improvements and variations are considered to be within the scope of the present disclosure.
[0169] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. Also, where features or aspects of the invention are described in terms of Markush groupings, those skilled in the art will recognize that the invention is also described in terms of any individual member or subgroup of members of the Markush grouping.
Claims
1. A method of treating hepatitis delta virus (HDV) infection in a human subject, comprising subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a until one or more of the following is achieved: a sustained reduction in HDV viral load or a reduction in HDV RNA to undetectable levels.
2. 2. The method of claim 1, wherein the pegylated interferon lambda-1a is administered for at least 12 weeks, or 24 weeks, or 36 weeks, or 48 weeks, or 54 weeks, or from 12 weeks to 96 weeks.
3. 2. The method of claim 1, wherein pegylated interferon lambda-1a is administered at a dose of 180 micrograms once a week (QW) or 90 micrograms twice a week; or 80 micrograms twice a week or 180 micrograms each week.
4. 2. The method of claim 1, wherein pegylated interferon lambda-1a is administered at a dose of 120 micrograms QW or at a dose of 60 micrograms twice weekly or 70 micrograms twice weekly or 120 micrograms each week.
5. 2. The method of claim 1, wherein the method comprises administering (i) 160 to 180 micrograms pegylated interferon lambda-1a per week in a first treatment period, followed by 150 to 70 micrograms per week in a second treatment period; or (ii) 180 micrograms per week in a first treatment period, followed by 170 to 120 micrograms per week in a second treatment period, wherein the doses of each of (i) and (ii) may be divided into more than one administration per week.
6. Subjects had a score of ≥ 500 / mm at the end of the first treatment period. 3 ~<750 / mm 3 or ≧400 / mm 3 ~<650 / mm 3 or ≧400 / mm 3 ~<850 / mm 3 2. The method of claim 1, wherein the subject is administered pegylated interferon lambda-1a for a second treatment period if the subject has an absolute neutrophil count (ANC) of 0.05-0.
05.
7. Target is <500 / mm 3 If the subject has an ANC of >1000 / mm, administration is discontinued. 3 and then re-start dosing for a second treatment period or until the subject achieves a baseline <400 / mm 3 If the subject has an ANC of >750 / mm, administration is discontinued. 3 6. The method of claim 5, wherein administration is interrupted until a patient achieves a median survival of 10 days and then administration is resumed for a second treatment period.
8. 6. The method of claim 5, wherein if the subject has a platelet level <50,000, the subject is administered pegylated interferon lambda-1a for a second treatment period, or if the subject has a platelet level <25,000, the subject is discontinued from treatment.
9. 6. The method of claim 5, wherein if the subject has ALT (or AST) > 15-20 x ULN and TBILI and / or INR < Grade 2, then suspend administration to the subject until ALT / AST < 10 x ULN and then resume administration for a second treatment period, or if the subject has a second ALT (or AST) > 15-20 x ULN and TBILI and / or INR < Grade 2, then suspend administration to the subject until ALT / AST < 10 x ULN and then resume administration for a second treatment period.
10. 6. The method of claim 5, wherein if the subject experiences an adverse event >= Grade 3, the subject is discontinued from dosing until the event resolves or is <= Grade 1, and then dosing is resumed for a second treatment period.
11. 11. The method of claim 10, wherein if the subject experiences a second adverse event of >= Grade 3, the subject is discontinued from dosing and then dosing is resumed for a third treatment period after the adverse event resolves or improves by one grade.
12. 2. The method of claim 1, comprising administering pegylated interferon lambda-1a at 120 micrograms / week for a first treatment period, then 80 micrograms / week for a second treatment period; or 180-120 micrograms / week for the first treatment period, then 120-80 micrograms / week for the second treatment period, wherein each dose may be divided into more than one administration per week.
13. 13. The method of claim 5 or 12, wherein the first treatment period is longer than the second treatment period, the second treatment period is longer than the first treatment period, or the first treatment period and the second treatment period are of the same length of time.
14. 13. The method of claim 5 or 12, wherein the first treatment period is for a period of at least 1 week, at least 2 weeks, at least 6 weeks, or at least 8 weeks.
15. 6. The method of claim 5, wherein the first treatment period is for a period of 8 to 12 weeks.
16. 6. The method of claim 5, wherein the method further comprises administering pegylated interferon lambda-1a at 80 micrograms to 120 micrograms per week in a third treatment period.
17. 2. The method of claim 1, wherein the method comprises administering pegylated interferon lambda-1a at a first dose of 180 micrograms in a first treatment period, a second dose of 170-120 micrograms / week in a second treatment period, and a third dose of 120-80 micrograms / week in a third treatment period.
18. 18. The method of claim 17, wherein the first treatment period is from 1 to 12 weeks, 2 to 18 weeks, 4 to 8 weeks, 1 to 4 weeks, or 6 to 12 weeks in duration.
19. 13. The method of any one of claims 1 to 12, wherein the treatment results in a reduction in HDV viral load in the subject of at least 2.0 log HDV RNA IU / mL serum.
20. 13. The method of any one of claims 1 to 12, wherein the treatment results in an HDV viral load that is below the limit of detection.
21. 13. The method of any one of claims 1 to 12, wherein prior to initiation of treatment, the subject has a serum alanine aminotransferase (ALT) level above the upper limit of normal (ULN), and the course of treatment improves serum ALT levels in the subject to a level within the ULN.
22. The method of any one of claims 1 to 12, wherein the method further comprises administering to the subject a nucleoside or nucleotide analogue.
23. 23. The method of claim 22, wherein the nucleoside or nucleotide analog is lamivudine, adefovir, telbivudine, entecavir or tenofovir.
24. The method of any one of claims 1 to 12, wherein the subject has compensated liver disease with or without cirrhosis.
25. 25. The method of claim 24, wherein the subject has compensated liver disease with cirrhosis.
26. Before treatment, subjects were up to approximately 10 4 The method of any one of claims 1 to 12, having a serum or plasma baseline viral load of HDV RNA copies / mL.
27. The method of claim 1, 3 or 4, wherein a sustainable viral response (DVR) is observed in the subject following administration.
28. 28. The method of claim 27, wherein the DVR is from about 16 to about 45% or from about 36 to about 45%.
29. 28. The method of claim 27, wherein DVR is observed in the subject from about 1 week to about 24 weeks after treatment.
30. 10. The method of claim 1, wherein administration of pegylated interferon lambda-1a results in milder and / or less frequent flu-like and psychiatric symptoms compared to treatment with interferon alpha.
31. 13. The method of claim 5 or 12, wherein elevated bilirubin levels and / or elevated ALT levels in the subject are normalized by dose reduction.
32. 32. The method of claim 31, wherein the subject has about an 11% to about 14% chance of treatment resulting in normalization of ALT levels.
33. Treatment is >= 2 Log 10 The method of any one of claims 1 to 12, which results in a HDV RNA reduction of 100%.
34. Treatment results in >1 log increase in HBsAg in subjects 10 The method of any one of claims 1 to 12, resulting in a reduction.
35. 35. The method of claim 34, wherein the subject's HBsAg levels continue to decrease following treatment.
36. -1.63 to -2.35log 10 4. The method of claim 3, wherein a mean reduction in HDV RNA is observed in subjects with 48 weeks of treatment.
37. A method of treating hepatitis delta virus (HDV) infection comprising administering about 80 to about 240 μg of pegylated interferon lambda-1a per week for at least 4 weeks, wherein the subject exhibits a sustainable viral response (DVR) 1 day to 24 weeks after the last administration.
38. DVR is HDV RNA BLQ; 2 log 10 reduction of HDV 2 log in viral load 10 or greater reduction; ALT normalization; ALT normalization plus >2 log 10 38. The method of claim 37, comprising one or more of the following post-treatment responses: reduction or clinically significant viral load reduction.
39. Viral load reduction of -1.09 to -2.08 or ~1.63 logs 10 ~ -2.3 logs 10 39. The method of claim 38, wherein:
40. 2 log HDV RNA in subjects 10 39. The method of claim 38, wherein the likelihood of treatment resulting in a reduction of or greater than about 12.1% to about 42.4%.
41. 40. The method of claim 38, wherein the likelihood of the treatment resulting in HDV RNA that is BLQ in the subject is between 15.1% and about 39.4%.
42. Approximately -1.18 logs 10 HDV RNA ~ approx. -2.35log 10 39. The method of claim 38, wherein HDV RNA viral load reduction is observed at 48 weeks of treatment.
43. Subjects who were on treatment had ALT normalization and >2 log after the last dose. 10 40. The method of claim 38, wherein the likelihood of reduction is increased.
44. 44. The method of claim 43, wherein the final administration is between week 4 and week 48 of administration.
45. 13. The method of claim 1, wherein in a subject, when administered at 180 mcg / week, treatment results in about a 36-45% chance of ALT normalization after 24 weeks of administration.
46. 46. The method of claim 45, wherein a transient ALT increase occurs during treatment, followed by normalization after treatment.
47. 47. The method of claim 46, wherein the transient ALT increase is greater than about 300-1100% above previous levels or baseline.
48. 2. The method of claim 1, wherein the probability of subjects reducing to a second dose during treatment is about 26-36%; the probability of dosing interruption is about 5-9% or the probability of treatment discontinuation is about 21-26%.
49. 49. The method of claim 48, wherein the reduction, interruption and cessation is primarily due to hepatic adverse events.
50. 49. The method of claim 48, wherein the percentage of subjects administered a 180 mcg / week dose have one or more of the following: dose reduction (about 30-36%), treatment interruption (about 7-9%), and treatment discontinuation (about 21-24%).
51. 49. The method of claim 48, wherein the percentage of subjects administered a 120 mcg / week dose have one or more of the following: dose reduction (about 26-30%), treatment interruption (about 5-9%), and treatment discontinuation (about 24-26%).
52. The initial dose of 180 micrograms / week was administered, and after the last dose, the patient had a high (>4 log 10 2. The method of claim 1, wherein 38-43% of subjects who had a baseline viral load achieved an HDV RNA level of BLQ at week 48.
53. The initial dose of 180 micrograms / week was administered, and after the last dose, the patient had a high (>4 log 10 2. The method of claim 1, wherein 25-29% of subjects who had a baseline viral load achieved HDV RNA levels of BLQ at 24 weeks post-treatment.
54. The initial dose of 180 micrograms / week was administered, and after the last dose, low (≦4 log 10 2. The method of claim 1, wherein 33-40% of subjects who had a baseline viral load achieved an HDV RNA level of BLQ at week 48.
55. The initial dose of 180 micrograms / week was administered, and the low (≦4 log 10 2. The method of claim 1, wherein 50-60% of subjects who had a baseline viral load achieved HDV RNA levels of BLQ at 24 weeks post-treatment.
56. 10. The method of claim 1, wherein 25-29% of subjects who received an initial dose of 180 micrograms / week and had a high (>4 log) baseline viral load after the last dose achieved undetectable HDV RNA levels after 48 and 24 weeks of treatment.
57. The initial dose of 180 micrograms / week was administered, and after the last dose, low (≦4 log 10 2. The method of claim 1, wherein 33-40% of subjects who had a baseline viral load achieved undetectable HDV RNA levels after 48 weeks and 24 weeks of treatment.
58. Between 16 and 21% of subjects receiving an initial dose of 120 micrograms / week achieved HDV RNA levels of BLQ; between 21 and 29% of subjects receiving an initial dose of 120 micrograms / week achieved HDV RNA levels of >2 log 10 11-14% of subjects receiving an initial dose of 120 micrograms / week achieved ALT normalization and 5-7% of subjects receiving an initial dose of 120 micrograms / week achieved ALT normalization + > 2 log reduction. 10 10. The method of claim 1, wherein one or more of the outcomes of achieving a reduction is obtained after the last administration.
59. Sixteen to 21% of subjects receiving an initial dose of 180 micrograms / week achieved HDV RNA levels of BLQ; 11 to 14% of subjects receiving an initial dose of 180 micrograms / week achieved HDV RNA levels of >2 log 10 26-36% of subjects receiving an initial dose of 180 micrograms / week achieved ALT normalization and 11-14% of subjects receiving an initial dose of 180 micrograms / week achieved ALT normalization + ≧2 log reduction. 10 10. The method of claim 1, wherein one or more of the outcomes that achieve a reduction is achieved 24 weeks after the last administration.
60. 36-45% of subjects receiving a starting dose of 180 micrograms / week achieved HDV RNA levels of BLQ; 50-64% of subjects receiving a starting dose of 180 micrograms / week achieved HDV RNA levels of ≥ 2 log 10 14-18% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization and 14-18% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization + ≧2 log 10 10. The method of claim 1, wherein one or more of the outcomes of achieving a reduction is obtained after the last administration.
61. Between 36 and 45% of subjects receiving a starting dose of 180 micrograms / week achieved HDV RNA levels of >2 log 10 36-45% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization and 29-36% of subjects receiving a starting dose of 180 micrograms / week achieved ALT normalization +> 2 log reduction. 10 10. The method of claim 1, wherein one or more of the outcomes that achieve a reduction is achieved 24 weeks after the last administration.
62. 2. The method of claim 1, wherein the subject has a baseline Child-Turcotte-Pugh score of 5-6 (Class A), 1-2, 1-3, 2-4, 3-4, 2-5, 3-5, or 2-6.
63. 10. The method of claim 1, wherein the subject has been diagnosed with hepatitis by one or more of a liver biopsy, liver function test, ultrasound, hepatic venous pressure gradient (HVPG) measurement, ALT level, other blood test, or albumin level.
64. 64. The method of claim 63, wherein serum alanine aminotransferase (ALT) levels are measured within 24 weeks prior to treatment, at the start of treatment, within 24 months, 24 months to 1 month, or within 12 months to 1 day prior to treatment.
65. 2. The method of claim 1, wherein the subject's HDV titer increases from baseline before falling below baseline during the course of treatment, wherein the subject's HDV level increases by more than 10%, more than 25%, more than 50%, more than 75%, more than 100%, more than 150%, or more than 200% above baseline, or about 25-50% above baseline, or 25-100% above baseline, or 50-200% above baseline.
66. 66. The method of claim 65, wherein the subject's HDV titer increase occurs within two weeks of initiating treatment.
67. 67. The method of claim 66, wherein the subject's elevated HDV titer decreases to below baseline within 2 weeks or within 3 weeks of initiating treatment.
68. 70. The method of claim 69, wherein the subject exhibits improvement in one or more liver function parameters, wherein the improved liver function is an improvement in one or more serum markers.
69. (Not stated in the original text)
70. 69. The method of claim 68, wherein the one or more liver function parameters comprise one or more of serum albumin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin, alpha2-macroglobulin, apolipoprotein A1, haptoglobin, or gamma-glutamyl transpeptidase (GGT).
71. 10. The method of claim 1, wherein the subject shows improvement in liver fibrosis after or during treatment.
72. 72. The method of claim 71, wherein liver fibrosis is assessed by one or more of biopsy with histology, transient ultrasound elastography or magnetic resonance elastography.
73. 72. The method of claim 71, wherein the improvement in liver fibrosis is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, 5-40%, 10-50, 50-100% improvement.
74. 72. The method of claim 71, wherein the improvement is measured by a functional parameter, wherein the functional parameter is one or more of an improvement in a serum marker or an improvement in liver fibrosis compared to baseline.
75. 75. The method of claim 74, wherein the baseline is one or more of the time at the start of treatment, another time point during the course of treatment, or a comparison with healthy subjects.
76. Subjects had log HDV RNA levels measured from baseline and during treatment 10 11. The method of claim 1, wherein if there is an increase of more than 10% by volume, the subject is discontinued treatment for 1 week, 2 weeks, 3 weeks, or until the subject's HDV viral load stabilizes to baseline levels.
77. 10. The method of claim 1, wherein after treatment, subjects have about a 24-32% chance of having an ALT flare from the baseline measurement, or a 12-16% chance from the end of treatment measurement.
78. 78. The method of claim 77, wherein the flare is a transient increase that is ≧4× the baseline value, end-of-treatment value, or upper limit of normal.
79. 78. The method of claim 77, wherein 44-92% of subjects experience ALT normalization after flare, where flare is measured at baseline or end of treatment.
80. 2. The method of claim 1, wherein prior to initiation of treatment, the subject has a serum alanine aminotransferase (ALT) level above the upper limit of normal (ULN), and the course of treatment improves the serum ALT level in the subject to a level that is within the ULN.
81. 64. The method of claim 63, wherein the biopsy is performed within 6 months, within 18 months, or within 1 day to 24 months prior to the treatment.
